Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals focuses on discovering, developing, and commercializing pharmaceutical products. Its drug candidates include Sotagliflozin for heart failure and type 1 diabetes, LX9211 for neuropathic pain, and LX2761 for gastrointestinal issues. These drugs are in various stages of development, from Phase I to Phase III clinical trials. The company has partnerships with Bristol-Myers Squibb and Genentech. Lexicon was founded in 1995 and is headquartered in Texas.
Overview
Strengths
- Paying down debt: long-term debt fell by 6.9 percentage points of total assets last year.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 8.6% in each of the last 6 years.
- Operating profit does not cover interest expense.
- Our discounted cash flow model finds no value to support the current price: operating profit does not cover interest expense.
- Shareholder dilution: the share count has grown by 24.4% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 6 years.
Key Financial Data